S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.17 (+0.72%)
AAPL   157.27 (-0.08%)
MSFT   273.01 (+0.29%)
META   200.41 (+1.31%)
GOOGL   102.05 (+0.82%)
AMZN   98.74 (+1.05%)
TSLA   191.29 (+4.39%)
NVDA   261.70 (+1.04%)
NIO   9.31 (+6.40%)
BABA   83.41 (+2.98%)
AMD   98.58 (+1.83%)
T   18.60 (+0.59%)
F   11.60 (+3.76%)
MU   59.02 (+2.39%)
CGC   1.96 (+5.38%)
GE   92.92 (+3.34%)
DIS   95.57 (+1.43%)
AMC   4.34 (+1.64%)
PFE   40.63 (-0.44%)
PYPL   75.13 (+2.62%)
NFLX   302.44 (-0.88%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.17 (+0.72%)
AAPL   157.27 (-0.08%)
MSFT   273.01 (+0.29%)
META   200.41 (+1.31%)
GOOGL   102.05 (+0.82%)
AMZN   98.74 (+1.05%)
TSLA   191.29 (+4.39%)
NVDA   261.70 (+1.04%)
NIO   9.31 (+6.40%)
BABA   83.41 (+2.98%)
AMD   98.58 (+1.83%)
T   18.60 (+0.59%)
F   11.60 (+3.76%)
MU   59.02 (+2.39%)
CGC   1.96 (+5.38%)
GE   92.92 (+3.34%)
DIS   95.57 (+1.43%)
AMC   4.34 (+1.64%)
PFE   40.63 (-0.44%)
PYPL   75.13 (+2.62%)
NFLX   302.44 (-0.88%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.17 (+0.72%)
AAPL   157.27 (-0.08%)
MSFT   273.01 (+0.29%)
META   200.41 (+1.31%)
GOOGL   102.05 (+0.82%)
AMZN   98.74 (+1.05%)
TSLA   191.29 (+4.39%)
NVDA   261.70 (+1.04%)
NIO   9.31 (+6.40%)
BABA   83.41 (+2.98%)
AMD   98.58 (+1.83%)
T   18.60 (+0.59%)
F   11.60 (+3.76%)
MU   59.02 (+2.39%)
CGC   1.96 (+5.38%)
GE   92.92 (+3.34%)
DIS   95.57 (+1.43%)
AMC   4.34 (+1.64%)
PFE   40.63 (-0.44%)
PYPL   75.13 (+2.62%)
NFLX   302.44 (-0.88%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.17 (+0.72%)
AAPL   157.27 (-0.08%)
MSFT   273.01 (+0.29%)
META   200.41 (+1.31%)
GOOGL   102.05 (+0.82%)
AMZN   98.74 (+1.05%)
TSLA   191.29 (+4.39%)
NVDA   261.70 (+1.04%)
NIO   9.31 (+6.40%)
BABA   83.41 (+2.98%)
AMD   98.58 (+1.83%)
T   18.60 (+0.59%)
F   11.60 (+3.76%)
MU   59.02 (+2.39%)
CGC   1.96 (+5.38%)
GE   92.92 (+3.34%)
DIS   95.57 (+1.43%)
AMC   4.34 (+1.64%)
PFE   40.63 (-0.44%)
PYPL   75.13 (+2.62%)
NFLX   302.44 (-0.88%)
OTCMKTS:NVZMY

Novozymes A/S - NVZMY Stock Forecast, Price & News

$48.46
-0.24 (-0.49%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$48.45
$49.43
50-Day Range
$47.30
$52.94
52-Week Range
$45.97
$71.14
Volume
28,321 shs
Average Volume
18,784 shs
Market Capitalization
$11.01 billion
P/E Ratio
N/A
Dividend Yield
1.18%
Price Target
$370.00

Novozymes A/S MarketRank™ Forecast

Analyst Rating
Hold
1.90 Rating Score
Upside/​Downside
663.5% Upside
$370.00 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.20mentions of Novozymes A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.56%
From $1.80 to $1.79 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars


NVZMY stock logo

About Novozymes A/S (OTCMKTS:NVZMY) Stock

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
Novozymes swells land holdings in Franklin County
No Major Surprises in Novozymes’ Q4 2022 Results
Novozymes A/S PT Lowered to DKK425 at Berenberg
Novozymes A/S (NVZMF) Q4 2022 Earnings Call Transcript
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
Novozymes delivers historically strong full-year results
Earnings Preview For Novozymes
Novozymes: Wonderful Company, Almost Reasonable Price
Novozymes and Chr. Hansen agree deal to merge
NVZMY Novozymes A/S
Catalysing carbon emission cuts at UNGA
See More Headlines
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Company Calendar

Last Earnings
4/29/2020
Ex-Dividend for 3/22 Dividend
3/03/2023
Ex-Dividend for 3/23 Dividend
3/06/2023
Today
3/21/2023
Dividend Payable
3/22/2023
Dividend Payable
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Employees
6,527
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$370.00
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$370.00
Forecasted Upside/Downside
+663.5%
Consensus Rating
Hold
Rating Score (0-4)
1.90
Research Coverage
10 Analysts

Profitability

Net Income
$500.53 million
Pretax Margin
24.92%

Debt

Sales & Book Value

Annual Sales
$2.38 billion
Cash Flow
$2.18 per share
Book Value
$8.51 per share

Miscellaneous

Free Float
N/A
Market Cap
$11.01 billion
Optionable
Not Optionable
Beta
0.72

Social Links


Key Executives

  • Ester Baiget
    President & Chief Executive Officer
  • Graziela Chaluppe dos Santos Malucelli
    Chief Operating Officer & Executive VP
  • Lars Green
    Chief Financial Officer & Executive Vice President
  • Claus Crone Fuglsang
    Executive Vice President-Research & Development
  • Anders Lund
    EVP & Head-Consumer Biosolutions













NVZMY Stock - Frequently Asked Questions

Should I buy or sell Novozymes A/S stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVZMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View NVZMY analyst ratings
or view top-rated stocks.

What is Novozymes A/S's stock price forecast for 2023?

10 Wall Street research analysts have issued 12-month price objectives for Novozymes A/S's stock. Their NVZMY share price forecasts range from $370.00 to $370.00. On average, they expect the company's stock price to reach $370.00 in the next twelve months. This suggests a possible upside of 663.5% from the stock's current price.
View analysts price targets for NVZMY
or view top-rated stocks among Wall Street analysts.

How have NVZMY shares performed in 2023?

Novozymes A/S's stock was trading at $50.46 at the beginning of 2023. Since then, NVZMY shares have decreased by 4.0% and is now trading at $48.46.
View the best growth stocks for 2023 here
.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 400 shares, a decline of 42.9% from the February 13th total of 700 shares. Based on an average daily trading volume, of 30,000 shares, the short-interest ratio is currently 0.0 days.
View Novozymes A/S's Short Interest
.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) announced its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a net margin of 20.08% and a trailing twelve-month return on equity of 26.96%.

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S announced a dividend on Thursday, March 2nd. Stockholders of record on Monday, March 6th will be paid a dividend of $0.5898 per share on Wednesday, March 22nd. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Friday, March 3rd.
Read our dividend analysis for NVZMY
.

What ETF holds Novozymes A/S's stock ?

Putnam BioRevolution ETF holds 3,439 shares of NVZMY stock, representing 3.58% of its portfolio.

Is Novozymes A/S a good dividend stock?

Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.57 per share and currently has a dividend yield of 1.17%.
Read our dividend analysis for NVZMY.

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $48.46.

How much money does Novozymes A/S make?

Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $11.01 billion and generates $2.38 billion in revenue each year.

How many employees does Novozymes A/S have?

The company employs 6,527 workers across the globe.

Does Novozymes A/S have any subsidiaries?
The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.
Read More
How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.

This page (OTCMKTS:NVZMY) was last updated on 3/21/2023 by MarketBeat.com Staff